Navigation Links
Unique Extracellular Matrix Used in Patient Successfully Treated for Flesh Eating Bacteria
Date:4/16/2013

COLUMBIA, Md., April 17, 2013 /PRNewswire/ -- A patient diagnosed with necrotizing fasciitis was successfully treated and discharged after ACell MatriStem was used in an effort to save her leg from amputation, reported Marcie Fraser of Your News Now.

Jonna Rue went to the hospital when her foot became blood-red and swollen. A flesh eating bacteria was quickly destroying the tissues in her leg. Doctors intervened surgically to remove a great deal of tissue in an attempt to stop the bacteria from spreading. Amputation of her lower leg was considered due to the extent of damage to her leg.

"Given the amount of overall tissue loss, it was not looking promising to keep her leg," Dr. Peter Fisk , Community Care General Surgeon said.

The wound was treated and MatriStem, the only commercially available form of urinary bladder matrix (UBM), was applied. Six weeks after the extracellular matrix (ECM) was applied to the patient's leg, the tissue was healed enough to skin graft and close the wound. The physician determined that amputation was no longer necessary.

"It is quite a grounding moment when we learn that our products have been used to help patients like Ms. Rue and are happy that she is recovering nicely. It is with a sense of pride and excitement to see the clinical outcomes when our technology is used to treat patients," Rodney Bosley , ACell President & COO said. "Results like these are driving our growth following the record product sales ACell achieved in 2012."

Necrotizing fasciitis, a rare condition of the skin and subcutaneous tissues, can rapidly spread across the body, leading to amputation or death.

MatriStem Products are porcine-derived extracellular matrix that maintain and support a healing environment through constructive remodeling, are available by prescription only in particle and sheet forms. Refer to IFU supplied with each device for indications, contraindications, and precautions.

About ACell  ACell, Inc. offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix products to repair and remodel damaged tissues in a broad range of applications. ACell's patented ECM devices address important clinical needs, while providing safe, effective, economical and therapeutic outcomes to the wound care and surgical communities. These devices, trademarked as MatriStem, are appropriate for acute wounds, chronic wounds and various surgical procedures. All MatriStem devices are made in the USA. For more information, call (800) 826-2926 or visit www.acell.com.


'/>"/>
SOURCE ACell, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ConnectBiotech.org Launched, a Unique Life Science Business Networking Site
2. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
3. Unique salt allows energy production to move inland
4. All Global Partners With HealthEngage to Provide Unique Web 2.0 Patient Insights
5. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
6. Unique properties of graphene lead to a new paradigm for low-power telecommunications
7. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
8. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
9. Boston College researchers unique nanostructure produces novel plasmonic halos
10. Unique Bed Bug Extermination Solution Revealed To The Public and Its Complimentary Sample Offered, MyCleaningProducts.com Shares Details Where to Get It
11. Verdad Media’s Unique MANIS Technology Means Better Reputation Management Results for Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team ... vascular grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. ... of treating coronary artery disease (CAD). Lam is an assistant professor at the ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):